Shana Kelley, PhD

Dr. Shana Kelley is a Distinguished Professor of Biochemistry, Pharmaceutical Sciences, Chemistry, and Biomedical Engineering at the University of Toronto. Dr. Kelley received her Ph.D. from the California Institute of Technology and was a NIH postdoctoral fellow at the Scripps Research Institute.

Her research interests include the development of new technologies for clinical diagnostics and drug delivery. Dr. Kelley’s work has been recognized with a variety of distinctions, including being named one of ‘Canada’s Top 40 under 40′, a NSERC E.W.R. Steacie Fellow, and the 2011 Steacie Prize. She has also been recognized with the Pittsburgh Conference Achievement Award, an Alfred P. Sloan Research Fellowship, a Camille Dreyfus Teacher-Scholar award, a NSF CAREER Award, a Dreyfus New Faculty Award, and was named a “Top 100 Innovator” by MIT’s Technology Review.

She is a founder of two molecular diagnostics companies, GeneOhm Sciences (acquired by Becton Dickinson in 2005) and Xagenic Inc.

Other Team Members

Kevin Empey, CPA, ICD.D

Supervisor, Brockville General Hospital

Har Grover, MBA, ICD.D

Executive Chairman and CEO, Scientus Pharma

John Morrison, BSc

Former Group President, Healthcare, MDS Inc.

Ken Lawless, MSc

President and CEO, Epitope Capital Corp.